Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand

Objectives: Evaluate and compare the efficacy and safety of molnupiravir and favipiravir in outpatients with mild to moderate COVID-19 and at risk of severe COVID-19. Methods: In an open-label, parallel-group, multicenter trial in Thailand, participants with moderate COVID-19 and at least one factor...

Full description

Bibliographic Details

Published in:	International Journal of Infectious Diseases
Main Authors:	Nicolas Salvadori, Gonzague Jourdain, Rungroj Krittayaphong, Taweegrit Siripongboonsitti, Subsai Kongsaengdao, Kriangsak Atipornwanich, Parichart Sakulkonkij, Nasikarn Angkasekwinai, Rujipas Sirijatuphat, Sarunyou Chusri, Tanavit Mekavuthikul, Anucha Apisarnthanarak, Sirawat Srichatrapimuk, Somnuek Sungkanuparph, Suppachok Kirdlarp, Thanyakamol Phongnarudech, Suraphan Sangsawang, Panuwat Napinkul, Jullapong Achalapong, Suwimon Khusuwan, Piyanut Pratipanawat, Pornboonya Nookeu, Namphol Danpipat, Pornvimol Leethong, Piya Hanvoravongchai, Pra-ornsuda Sukrakanchana, Prasert Auewarakul
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	Molnupiravir Favipiravir COVID-19 Outpatients Randomized controlled trial Thailand
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971224000924